Seeing further.


We’re advancing our RNA-based treatments so patients with cancer can enjoy the moments that matter.

Learn More

Transforming Immunity. Restoring Hope.

We’re committed to redefining the treatment of certain cancers and rare diseases.

Learn More

Scientists. Believers. People.

At Idera, we’re working hard to translate our nucleic acid science into life-changing medicines.

Discover Idera

The Latest

Keep up with what’s happening at Idera Pharmaceuticals.


Idera Pharmaceuticals Reports Fourth Quarter and Year End 2018 Financial Results and Provides Corporate Update

– ILLUMINATE-301 Enrollment on Track for Completion Q4 2019 – – ILLUMINATE-204 Enrollment… Read more 

Idera Pharmaceuticals Completes Enrollment Into the ILLUMINATE-204 Trial of the Combination of Tilsotolimod and Ipilimumab for Unresectable or Metastatic Melanoma Following Failure of PD-1 Inhibitor Treatment

- Results from the Phase 2 Expansion of ILLUMINATE-204 anticipated to be reported in the 4 th… Read more 

Idera Pharmaceuticals to Present at the 37th Annual J.P. Morgan Healthcare Conference

EXTON, Pa. , Jan. 04, 2019 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. (NASDAQ: IDRA) today… Read more 

Learn More


Idera Pharmaceuticals, Inc. Events

Idera Pharmaceuticals, Inc. Events… Read more 

Learn More